Our findings in the co-treatment trials suggest that a combined treatment of SLC-0111 plus the conventional chemotherapeutic agents could be beneficial in treating CRC if the tumor presents itself with a high expression status of the tumor-associated carbonic anhydrases. This evidence concerns the gene CCL21 and neoplasm.